Skip to Content
Merck
All Photos(1)

Key Documents

P8396

Sigma-Aldrich

Piperacillin sodium salt

penicillin analog

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C23H26N5NaO7S
CAS Number:
Molecular Weight:
539.54
Beilstein:
5373920
EC Number:
MDL number:
UNSPSC Code:
51282423
PubChem Substance ID:
NACRES:
NA.85

Quality Level

form

powder

solubility

H2O: soluble 50 mg/mL

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria

Mode of action

cell wall synthesis | interferes

storage temp.

2-8°C

SMILES string

[Na+].CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C([O-])=O)c4ccccc4)C(=O)C1=O

InChI

1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14-,15+,20-;/m1./s1

InChI key

WCMIIGXFCMNQDS-IDYPWDAWSA-M

Looking for similar products? Visit Product Comparison Guide

General description

Chemical structure: ß-lactam

Application

Piperacillin is a semisynthetic, broad-spectrum ureidopenicillin antibiotic. It is derived from ampicillin. It has been used in pharmacokinetic studies in order to optimize antimicrobial therapy in patients with sepsis. It is used to study piperacillin hypersensitivity reactions and to study multidrug-resistant organisms.

Biochem/physiol Actions

Piperacillin inhibits the last stage of bacterial cell wall synthesis by binding to certain penicillin-binding proteins (PBPs), which results in cell lysis. Cell lysis is mediated by bacterial cell wall autolytic enzymes. Piperacillin may interfere with autolysin inhibitors.

Packaging

1g,5g,10g

Other Notes

Keep container tightly closed in a dry and well-ventilated place.Keep in a dry place.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Zhiping Li et al.
European journal of clinical pharmacology, 69(6), 1223-1233 (2013-01-29)
To develop population pharmacokinetic (PK) models for piperacillin/tazobactam in neonates and infants of less than 2 months of age in order to determine the appropriate dosing regimen and provide a rational basis for the development of preliminary dosing guidelines suitable
João Gonçalves-Pereira et al.
PloS one, 7(11), e49845-e49845 (2012-11-28)
The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese intensive care units (ICU). We included 569 critically ill adult patients
Jennifer A Pratt et al.
Pediatric blood & cancer, 61(2), 366-368 (2013-09-17)
Neutropenic fever is a common complication of myelosuppressive therapy in pediatric oncology patients. Piperacillin-tazobactam (PIP/TAZO) is a broad spectrum antibiotic used for empiric treatment of neutropenic fever. We describe four cases of suspected PIP/TAZO induced nephrotoxicity occurring in children with
M A Zeitlinger et al.
The Journal of antimicrobial chemotherapy, 56(4), 703-708 (2005-08-27)
Pharmacokinetic (PK)/pharmacodynamic (PD) models have become increasingly important in optimizing antimicrobial therapy. This approach is highly recommended by regulatory authorities intending to force the evaluation of antimicrobial action at the site of infection. Clinical isolates of Pseudomonas aeruginosa and Staphylococcus
S Christian Cheatham et al.
International journal of antimicrobial agents, 41(1), 52-56 (2012-12-12)
The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Fourteen hospitalised patients weighing >120kg received piperacillin/tazobactam 4.5 g every 8 h (q8h) or 6.75 g q8h infused over

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service